Abstract
Respiratory syncytial virus (RSV) is a significant cause of severe pneumonia among infants under 6 months of age worldwide and maternal immunization is being considered as a realistic strategy for prevention. Several maternal RSV vaccine candidates are at advanced stages of clinical evaluation, with some showing promising results. However, gaps in knowledge of the factors likely to influence its effectiveness, might hinder the successful implementation of the maternal RSV vaccination program in Kenya...